Atropine Sulphate Fresenius 0.5 mg. 0.6 mg or 1.0 mg Injection
PDF Leaflet Revision Date: 15 June 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Used for parasympatholytic effects, including during anesthesia and as an antidote for poisoning.
Dosage (summary)
Adult: 0.3 to 0.6 mg IM/SC or IV before anesthesia; 0.6 to 1.2 mg IV post-op with neostigmine.
Onset of Action / Duration
Onset: 2-4 mins, Duration: 2-5 hours
Special Populations
- Children
- Elderly
- Downu2019s syndrome
Pregnancy & Breastfeeding
Crosses placenta; may cause fetal tachycardia. Avoid during breastfeeding due to infant sensitivity.
Key Drug Interactions
- Antimuscarinics
- Monoamine-oxidase inhibitors
- Antipsychotics
- Beta-blockers
Contraindications
- Hypersensitivity
- Closed-angle glaucoma
- Prostatic enlargement
- Paralytic ileus
- Myasthenia gravis
Common side effects
- Dry mouth
- Dizziness
- Confusion
- Tachycardia
- Urinary retention
Counselling Points
- Avoid driving or operating machinery
- Report any severe side effects
- Stay hydrated during treatment
Serious warnings
- Caution in cardiac insufficiency
- Risk of CNS effects
- Paradoxical AV block post-transplant
Important Disclaimer
The Atropine Sulphate Fresenius 0.5 mg. 0.6 mg or 1.0 mg Injection professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
